These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 19875584)

  • 21. The role of treatment to increase HDL-cholesterol and decrease triglyceride concentrations in prevention of coronary heart disease in Type 2 diabetes.
    Wild S; Byrne CD
    Diabet Med; 2004 Sep; 21 Suppl 4():8-11. PubMed ID: 15315518
    [No Abstract]   [Full Text] [Related]  

  • 22. Non-HDL cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes.
    Holman RR; Coleman RL; Shine BS; Stevens RJ
    Diabetes Care; 2005 Jul; 28(7):1796-7. PubMed ID: 15983339
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose atorvastatin therapy achieves 25% reduction in CV events in TNT substudy of diabetic patients.
    Cardiovasc J S Afr; 2006; 17(4):206-7. PubMed ID: 17001426
    [No Abstract]   [Full Text] [Related]  

  • 26. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of long-chain polyunsaturated higher ω-3 fatty acids, benfotiamine and α-lipoic acid on the lipid metabolism in patients with diabetes mellitus type 2 and cardiovascular autonomic neuropathy].
    Sergienko VA; Segin VB; Samir A; Sergienko AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(11):54-8. PubMed ID: 24429949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
    Thomason MJ; Colhoun HM; Livingstone SJ; Mackness MI; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Fuller JH;
    Diabet Med; 2004 Aug; 21(8):901-5. PubMed ID: 15270795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome?
    Windler E
    Atheroscler Suppl; 2005 Sep; 6(3):11-4. PubMed ID: 16046281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetic dyslipidemia and response to intensified glycemic treatment: why there are differences?
    Baroni MG
    J Endocrinol Invest; 2005 Nov; 28(10):869-70. PubMed ID: 16419487
    [No Abstract]   [Full Text] [Related]  

  • 31. Serum lipoprotein(a) is increased in hypertensive NIDDM patients.
    Hancu N; Netea MG; Iancu S
    Diabetes Care; 1995 Jun; 18(6):879-80. PubMed ID: 7555518
    [No Abstract]   [Full Text] [Related]  

  • 32. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).
    Robins SJ; Rubins HB; Faas FH; Schaefer EJ; Elam MB; Anderson JW; Collins D;
    Diabetes Care; 2003 May; 26(5):1513-7. PubMed ID: 12716814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.
    Sharma RK; Singh VN; Reddy HK
    Vasc Health Risk Manag; 2009; 5():793-9. PubMed ID: 19812691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia.
    Pirillo A; Catapano AL
    Atheroscler Suppl; 2013 Aug; 14(2):237-42. PubMed ID: 23958479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetic vascular disease.
    Feingold KR; Siperstein MD
    Adv Intern Med; 1986; 31():309-40. PubMed ID: 3511622
    [No Abstract]   [Full Text] [Related]  

  • 36. Impact of diabetes, high triglycerides and low HDL cholesterol on risk for ischemic cardiovascular disease varies by LDL cholesterol level: a 15-year follow-up of the Chinese Multi-provincial Cohort Study.
    Liu J; Wang W; Wang M; Sun J; Liu J; Li Y; Qi Y; Wu Z; Zhao D
    Diabetes Res Clin Pract; 2012 May; 96(2):217-24. PubMed ID: 22244364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is dyslipidaemia important if we control glycaemia?
    Schernthaner G
    Atheroscler Suppl; 2005 Sep; 6(3):3-10. PubMed ID: 16055391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
    Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of GLP-1 based therapies on diabetic dyslipidemia.
    Patel VJ; Joharapurkar AA; Shah GB; Jain MR
    Curr Diabetes Rev; 2014; 10(4):238-50. PubMed ID: 24998439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
    Shepherd J; Barter P; Carmena R; Deedwania P; Fruchart JC; Haffner S; Hsia J; Breazna A; LaRosa J; Grundy S; Waters D
    Diabetes Care; 2006 Jun; 29(6):1220-6. PubMed ID: 16731999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.